Literature DB >> 18060673

Assessment of user safety, exposure and risk to veterinary medicinal products in the European Union.

K N Woodward1.   

Abstract

Safety is an important part of veterinary drug assessment while user safety is a critical part of the overall safety assessment. In the European Union (EU), user safety is addressed through preclinical studies and by relationships with exposure but a key part of the process is the user safety assessment. EU user safety guidelines are available and these make certain recommendations but in places they lack detail and clarity. This paper seeks to examine the relevant factors that lie behind user risk assessments for veterinary medicinal products in general while focusing on EU requirements, the determination of risk management and risk communication strategies and how this relates to user safety assessment and pharmacovigilance responsibilities.

Mesh:

Substances:

Year:  2007        PMID: 18060673     DOI: 10.1016/j.yrtph.2007.10.007

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  3 in total

1.  Olaquindox disrupts tight junction integrity and cytoskeleton architecture in mouse Sertoli cells.

Authors:  Di Wu; Chun-Jie Huang; Xiao-Fei Jiao; Zhi-Ming Ding; Jia-Yu Zhang; Fan Chen; Yong-Sheng Wang; Xiang Li; Li-Jun Huo
Journal:  Oncotarget       Date:  2017-08-16

2.  Veterinary pharmacovigilance in sub-Sahara Africa context: a pilot study of adverse reactions to veterinary medicine in Cameroon.

Authors:  Mohamed Moctar Mouliom Mouiche; Badou Zaki Ndouoya Njingou; Frédéric Moffo; Serge Eugene Mpouam; Jean Marc Kameni Feussom; Julius Awah-Ndukum
Journal:  BMC Vet Res       Date:  2019-08-19       Impact factor: 2.741

3.  Comparative In vitro Metabolism of Enflicoxib in Dogs, Rats, and Humans: Main Metabolites and Proposed Metabolic Pathways.

Authors:  Josep Solà; Àngel Menargues; Josep Homedes; Marta Salichs; Maria Teresa Serafini; Gregorio Encina
Journal:  Drug Metab Lett       Date:  2021
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.